Personal Statement
Douglas Zatzick, M.D. is currently a professor in the Department of Psychiatry and Behavioral Sciences at University of Washington School of Medicine. Over the past two decades, he has developed a public health approach to trauma-focused research and clinical work that has emphasized clinical epidemiologic, functional outcome, and early intervention studies of posttraumatic stress disorder (PTSD) and related co-morbid conditions. From 2009-2012, he served as Chairperson of the National Institute of Mental Health, Services in Non-specialty settings (NIMH, SRNS) Study Section. He served on the congressionally mandated United States Institute of Medicine four-year ongoing assessment of PTSD treatment, and the World Health Organization PTSD Guideline Development Group. He has participated in disaster relief and early intervention efforts after Hurricane Katrina and the January 2010 Haiti earthquake. He was medical director of the University of Washington’s Harborview Level 1 Trauma Center Psychiatric Consultation Liaison Service, and in this capacity provided front-line clinical services to ethno-culturally diverse acutely injured trauma survivors. As a part of multidisciplinary collaborative group that includes empiricist trauma surgical policy makers, he is working to use clinical trial results to influence policy for PTSD screening and intervention at trauma centers throughout the United States.
Alysha Thompson, PhD is the Clinical Director and attending psychologist on the Psychiatry and Behavioral Medicine Unit at Seattle Children’s Hospital and Associate Professor in the Department of Psychiatry and Behavioral Sciences at University of Washington. Prior to joining the staff and faculty at Seattle Children’s/UW, she was a staff psychologist on the Adolescent Inpatient Unit at Bradley Hospital and Clinical Assistant Professor in the Department of Psychiatry and Human Behavior at Brown University. She is an active participant in training future psychiatrists and psychologists and currently serves as Chair-Elect of the Acute, Intensive, and Residential Services Special Interest Group of Division 53 of the American Psychological Association, a national group of psychologists.
Dr. Thompson has authored multiple publications regarding inpatient psychiatric treatment for youth and has forged collaborations with psychiatrists and psychologists working in inpatient psychiatry and acute care around the country. Recently, she co-edited the Handbook of Evidence-Based Inpatient Mental Health Programs for Children and Adolescents. In addition, she is actively engaged in advocacy efforts regarding improvement the mental health care system for youth. She is passionate about providing quality services to youth experiencing severe mental health crises and has specific areas of expertise in working with youth with trauma histories and suicidality.
Dr. Thompson completed her graduate education at Suffolk University in Boston in clinical psychology with an emphasis in child and adolescent clinical psychology. She completed residency in pediatric psychology at Rush University Medical Center in Chicago and went on to complete a fellowship in clinical psychology with an emphasis in trauma in children and adolescents at the Trauma Center at Justice Resource Institute.
Personal Statement
My area of expertise is addiction psychiatry.
Personal Statement
My research aims to improve the public health impact of evidence-based behavioral health interventions for addressing comorbidities common among ethnoculturally diverse and underserved victims of trauma, including PTSD, depression, suicidal ideation, and risky substance use. I study the integration of behavioral interventions into general medical settings, with an emphasis on provider-centered training methods to support the delivery of patient-centered interventions. My current interest is in harnessing technologic innovations in machine learning and artificial intelligence, along with user-centered design, to enhance suicide prevention training scalability and sustainability. https://darnell.psychiatry.uw.edu/
I am a Professor in the Department of Psychiatry and Behavioral Sciences and I work as the Deputy Associate Chief of Staff for Mental Health at the VA Puget Sound Health Care System. I am a licensed clinical psychologist. My research is focused on studying mental health technologies to support Veterans, Service Members, their families, and the health care staff that treat them. I research mobile applications, virtual reality, virtual standardized patients, and other innovative approaches to improve mental health education and services. I have conducted DoD and VA funded research and focus on applied interventions that may have promise to make a difference in the lives of those we serve. I am an Army Veteran and current behavioral health officer in the Washington State Army National Guard.
Personal Statement
Dr. Sylvers serves as the Director of Psychology Training at the Veterans Affairs Puget Sound Health Care System, American Lake Division. His primary research interests include personality and its relation to treatment outcomes, treatment outcomes related to trauma and anxiety related disorders, and the etiology and treatment of aggressive behavior. Dr. Sylvers also serves as a consultant for the Department of Veterans Affairs Acceptance and Commitment Therapy for Depression training initiative.
Personal Statement
Over the last 25 years, my work has focused on relationships between stress and health in several risk groups (spouse caregivers of persons with Alzheimer’s disease, medical students, psychiatric/medical outpatients/inpatients, air traffic controllers, and camp counselors). We have developed and/or revised measures of medical student stress, caregiver burden, patient anger/dyscontrol, process coping, appraisal, neuropsychological function and physician awareness of patient problems. These measures have been used by university researchers, insurance companies, pharmaceutical companies in clinical trials, prisons, nursing homes/long term care, rehabilitation facilities, and public health organizations. These psychosocial and behavioral measures have been shown to predict and be predicted by physiological and cognitive measures. We have also focused on moderators of such relationships, such as gender, personality, and co-morbidities. We have used primarily multicohort long-term studies that allow for interactions between exposures to stressors, hard-wired vulnerabilities, and more temporal resources. We attempted to identify mechanisms that can be potentially altered to have long-term public health significance in persons under chronic stress. I have also attempted to isolate groups that are at high risk for negative outcomes. In a perfect world, interventions should be used to help all persons who have deleterious responses to stress, but society cannot afford this. For this reason, the identification of high risk groups is imperative for maximizing the effect of interventions.
My research program’s long range goal is to better understand the mechanisms by which chronic stress translates into physical, mental, or cognitive health problems. We are examining caregivers of spouses with AD and demographically-similar spouse non-caregivers across time and assessing the degree to which elevated depression, stress hormones, inflammation, and insulin resistance in caregivers predict cognitive decline in caregivers relative to non-caregivers. We are also attempting to replicate our earlier work that showed that chronic stress and chronic disease moderate each other’s physiological risks. For example, physiological dysregulation that is specific to a disease (e.g., metabolic syndrome with CHD, blood pressure reactivity with hypertension, and immune function with cancer history, HbA1c with diabetes) is exacerbated in caregivers with a chronic disease relative to non-caregivers with a chronic disease, but no such differences occur in caregivers versus non-caregivers without a chronic disease. Finally, we are examining a large cohort of older adults sampled from various U.S. communities in order to assess the influence of life stressors on long term cognitive function and potential mediators of such changes.
Personal Statement
I am Co-Director of the VA VISN 20 (Northwest Network) Mental Illness Research, Education, and Clinical Center (MIRECC). I am also the Friends of Alzheimer’s Research Professor of Psychiatry and Behavioral Sciences at the University of Washington (UW) School of Medicine and am Associate Director of the UW Alzheimer’s Disease Research Center. My research over the past 30 years has addressed cognitive and behavioral problems and cerebrospinal fluid (CSF) biomarkers in neurodegenerative dementing disorders such as Alzheimer’s disease. More recently, my research has focused on combat trauma posttraumatic stress disorder and the clinical phenomenology as well as neuroimaging and CSF biomarkers of neurodegeneration in combat blast concussion mild traumatic brain injury and in Gulf War Veterans Illness. I continue to conduct single site as well as multi-site large scale studies of CSF biomarkers and pharmacological treatment trials for behavioral disorders and traumatic brain injury.
Summary of my research program:
Blast Concussion Mild Traumatic Brain Injury (mTBI)
Strategies: multimodal neuroimaging: structural and functional magnetic resonance imaging (diffusion tensor imaging [DTI], DTI tractography, macromolecular proton fraction mapping, resting state and task-based functional MRI; susceptibility-weighted imaging, FDG-positron emission tomography [PET]; cerebrospinal fluid and plasma biomarkers; genetic risk factors; clinical, neurocognitive and behavioral assessments,
Gulf War Veterans Illness (GWVI)
Strategies: multimodal neuroimaging and CSF and plasma biomarkers as described above, epigenetics, pain sensitivity testing and ability to activate endogenous opioid systems, and functional activity of paraoxonase I, the enzyme that metabolizes organophosphate insecticides.
Cerebrospinal Fluid and Plasma Biomarkers of Neurodegeneration Strategies: Bead-based multiplex assays using Luminex and Meso-Scale platforms, Quanterix ultra-sensitive platform, and broad-scale mass spectrometry for measurement of proteins, circulating RNAs, microRNAs in collaboration with VA/UW and Institute for Systems Biology investigators.
Pharmacologic Treatment of Disruptive Agitation in Alzheimer’s Disease (AD)
Strategies: Alzheimer’s Disease Cooperative Study multi-center randomized placebo-controlled trial of the alpha-1 adrenoreceptor antagonist, prazosin, for treatment of disruptive agitation in AD.
